ReviewOsteoporosis and sarcopenia2025
Epidemiology of sarcopenia: A narrative review.
Review in Osteoporosis and sarcopenia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiographic paraspinal muscle size in adult spinal deformity: a systematic review and meta-analysis.Spine deformity · 2026Pooled it
- Sleep disturbances, inflammation, and muscle function in older adults with sarcopenia.Sleep & breathing = Schlaf & Atmung · 2026Article
- The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.Obesity (Silver Spring, Md.) · 2026Review
- Age, Not Sex, Drives Sarcopenia Severity in Mexican Older Adults with a Health Insurance Plan.Geriatrics (Basel, Switzerland) · 2026Article
- Sarcopenia and Frailty in COPD: Mechanisms, Relationship with Malnutrition and Potential Therapeutic Interventions.Nutrients · 2026Review
- Broccoli-Derived Peptides and Leucine in Combination Ameliorate D-Galactose-Induced Sarcopenia in Mice.Nutrients · 2026Article
- Distribution of Muscle Mass and Fat Mass to Identify the Risk of Sarcopenia and Sarcopenic Obesity in Adults via Machine Learning.Healthcare (Basel, Switzerland) · 2026Article
- Climate Change and Sarcopenia: Mechanisms, Vulnerabilities, and Public Health Implications.Calcified tissue international · 2026Review
- Skeletal and cardiac muscle longitudinal associations in the Baltimore Longitudinal Study of Aging (BLSA).BMC medicine · 2026Article
- Evaluation of the knowledge, perception, and practice of nurses regarding sarcopenia: a descriptive study.BMC geriatrics · 2026Article
- PDMD: A Comprehensive Repository of Plants Reported for Skeletal Muscle-related Ailments.Current drug targets · 2026Article
- Peri-operative nutrition in femoral neck fracture arthroplasty: a pragmatic framework to mitigate dual-hit catabolism and improve outcomes.Orthopedic reviews · 2026Article
- Sleep Disturbances and Sarcopenia in Older Adults: Clinical Associations, Potential Mechanisms, and Management Strategies.International journal of general medicine · 2026Review
- Roles of DRP1 and the fission protein interactome as regulators of cellular stability and sarcopenia in skeletal muscle aging.Aging advances · 2025Article
- Association between triglyceride-glucose muscle-loss index (TyG-MLI) and incident cardiovascular disease: a prospective cohort study in the UK biobank.Cardiovascular diabetology · 2025Article
- Sex-specific associations between type 2 diabetes and muscle health in middle-aged adults.Diabetology & metabolic syndrome · 2025Article
- Identification of Mitochondria- and Macrophage Activation-Related Hub Genes in Sarcopenia.IET systems biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is a progressive loss of skeletal muscle mass and strength that contributes to adverse outcomes such as falls, fractures, and mortality in aging populations. Its prevalence varies widely across studies, influenced by intrinsic factors (eg, age, comorbidities, lifestyle), environmental conditions (eg, urban-rural differences, institutionalization), and the diagnostic criteria applied. This review synthesizes evidence mainly from systematic reviews and meta-analyses to examine how these factors shape the epidemiology of sarcopenia. The use of different definitions, such as EWGSOP 1/2, AWGS 2014/2019, IWGS, and FNIH, leads to large variations in prevalence estimates. This limits regional comparisons and hampers surveillance. The review also highlights key risk factors such as physical inactivity, malnutrition, smoking, irregular sleep, and cognitive impairment, although the overall certainty of evidence remains low to moderate. These findings emphasize the need for harmonized diagnostic standards and greater methodological consistency in future studies. Clinically, integrating sarcopenia screening into routine care and implementing targeted lifestyle interventions may help reduce disease burden. Future longitudinal and interventional research is essential to clarify causal pathways and guide effective public health strategies for sarcopenia prevention and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.